Stopping diabetes in its tracks: Autologous non-myeloablative stem cell transplantation

Regenerative Medicine

Volumn 2, Issue 5, 2007, Pages 845-851

  Fousteri, Georgia ^a   Hayek, Alberto ^b   von Herrath, Matthias ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b Whittier Institute for Diabetes   (United States)

Author keywords

Anti CD3; Anti thymocyte globulin; Cyclophosphamide; Diabetes; Human trial; Non myeloablative stem cell transplantation; Tregs

Indexed keywords

C PEPTIDE; CD3 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; INSULIN; NICOTINAMIDE; THYMOCYTE ANTIBODY;

ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BYSTANDER EFFECT; CLINICAL TRIAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STEM CELL MOBILIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS REACTIVATION;

AUTOANTIBODIES; C-PEPTIDE; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DIABETES MELLITUS, TYPE 1; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, BIOLOGICAL; STEM CELLS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 35048846482     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.2.5.845     Document Type: Article

References (43)

1. Bresson D, von Herrath M: Moving towards efficient therapies in Type 1 diabetes: to combine or not to combine? Autoimmun. Rev. 6(5), 315-322 (2007).
2. Martin S, Schernthaner G, Nerup J et al.: Follow-up of cyclosporin A treatment in Type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects. Diabetologia 34(6), 429-434 (1991).
3. Soulillou JP, Giral M: Clinical immunosuppression 2000. Transpl. Int. 13(Suppl.1), S20-S23 (2000).
4. Soulillou JP, Giral M: Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 72(Suppl. 12), S89-S93 (2001).
5. Bluestone JA, Tang Q: Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T-cells. Proc. Natl Acad. Sci. USA 101 (Suppl. 2) 14622-14626 (2004).
6. Tang Q, Bluestone JA: Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev. 212, 217-237 (2006).
7. Bresson D, Togher L, Rodrigo E et al.: Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune, diabetes by inducing Tregs. J. Clin. Invest. 116(5), 1371-1381 (2006).
8. Homann D, Holz A, Bot A et al.: Autoreactive CD4+ T-cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity 11(4), 463-472 (1999).
9. von Herrath M, Homann D: Tolerance tag team. Nat. Med. 10(6), 585-587 (2004).
10. Harlan DM, von Herrath M: Immune intervention with anti-CD3 in diabetes. Nat. Med. 11(7), 716-718 (2005).
11. von Herrath MG, Coon B, Wolfe T, Chatenoud L: Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J. Immunol. 168(2), 933-941 (2002).
12. Herold KC, Taylor L: Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation? Immunol. Res. 28(2), 141-150 (2003).
13. Bluestone JA, Abbas AK: Natural versus adaptive regulatory T-cells. Nat. Rev. Immunol. 3(3), 253-257 (2003).
14. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC: TCR stimulation with modified anti-CD3 mAb expands CD8+ T-cell population and induces CD8+CDA+ Tregs. J. Clin. Invest. 115(10), 2904-2913 (2005).
15. Bisikirska BC, Herold KC: Use of anti-CD3 monoclonal antibody to induce immune regulation in Type 1 diabetes. Ann. NY Acad. Sci. 1037, 1-9 (2004).
16. von Herrath M: El-INT (Transition Therapeutics/Novo Nordisk). Curr. Opin. Investig. Drugs 6(10), 1037-1042 (2005).
17. Triplitt CL: New technologies and therapies in the management of diabetes. Am. J. Manag. Care 13(Suppl. 2), S47-S54 (2007).
18. Bresson D, von Herrath M: Immunotherapy after recent-onset Type 1 diabetes: combinatorial treatment for achieving long-term remission in humans? Rev. Diabet. Stud. 1(3), 108-112 (2004).
19. Voltarelli JC, Couri CE, Stracieri AB et al.: Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed Type 1 diabetes mellitus. JAMA 297(14), 1568-1576 (2007).
20. Gratwohl A, Passweg J, Bocelli-Tyndall C et al.: Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 35(9), 869-879 (2005).
21. Hough RE, Snowden A Wulffraat NM: Haemopoietic stem cell transplantation in autoinumme diseases: a European perspective. Br. J. haematol. 128(4), 432-459 (2005).
22. Pietropaolo, M, Barinas-Mitchell E, Kuller LH: The heterogeneity of diabetes: unraveling a dispute: is systemic inflammation related to islet autoimmunity? Diabetes 56(5), 1189-1197 (2007).
23. Burt RK, Traynor A, Statkute L et al.: Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 295(5), 527-535 (2006).
24. Oyama Y, Craig RM, Traynor AE et al.: Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 128(3), 552-563 (2005).
25. Snowden JA, Passweg J, Moore JJ et al.: Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J. Rheumatol. 31(3), 482-488 (2004).
26. Martin S, Pawlowski B, Greulich B et al.: Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care 15(1), 66-74 (1992).
27. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes 37(11), 1574-1582 (1988).
28. Tarbell KV, Petit L, Zuo X et al.: Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T-cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204(1), 191-201 (2007).
29. Fousteri G, von Herrath M, Bresson D: Mucosal exposure to antigen: cause or cure of Type 1 diabetes? Curr. Diab. Rep. 7 (2), 91-98 (2007).
30. Miller A, Lider O, Weiner HL: Antigen-driven bystander suppression after oral administration of antigens. J. Exp. Med. 174(4), 791-798 (1991).
31. Legge KL, Gregg RK, Maldonado-Lopez R et al.: On the role of dendritic cells in peripheral T-cell tolerance and modulation of autoimmunity. J. Exp. Med. 196(2), 217-227 (2002).
32. Rutella S, Danese S, Leone G: Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108(5), 1435-1440 (2006).
33. Steinman RM, Hawiger D, Nussenzweig MC: Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685-711 (2003).
34. Fisson S, Djelti F, Trenado A et al.: Therapeutic potential of self-antigen-specific CD4+ CD25+ regulatory T-cells selected in vitro from a polyclonal repertoire. Eur. J. Immunol. 36 (4), 817-827 (2006).
35. Herold KC, Gitelman SE, Masharani U et al.: A single course of anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of Type 1 diabetes. Diabetes 54(6), 1763-1769 (2005).
36. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al.: Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N. Engl. J. Med. 352(25), 2598-2608 (2005).
37. Herold KC, Hagopian W, Auger JA et al.: Anti-CD3 monoclonal antibody in new-onset Type 1 diabetes mellitus. N Engl. J. Med. 346(22), 1692-1698 (2002).
38. Sherry NA, Kushner JA, Glandt M et al.: Effects of autoimmunity and immune therapy on β-cell turnover in Type 1 diabetes. Diabetes 55(12), 3238-3245 (2006).
39. Tsai EB, Sherry NA, Palmer JP, Herold KC: The rise and fall of insulin secretion in Type 1 diabetes mellitus. Diabetologia 49 (2), 261-270 (2006).
40. O'Reilly LA, Gu D, Sarvetnick N et al.: α-cell neogenesis in an animal model of IDDM. Diabetes 46(4), 599-606 (1997).
41. Effects of insulin in relatives of patients with Type 1 diabetes mellitus. N. Engl. J. Med. 346(22), 1685-1691 (2002).
42. Cabrera-Rode E, Molina G, Arranz C et al.: Effect of standard nicotinamide in the prevention of Type 1 diabetes in first degree relatives of persons with Type 1 diabetes. Autoimmunity 39(4), 333-340 (2006).
43. Janeway C, Travers P, Walport M, Shlomchik M: Immunobiology, 5th Edition. Garland Science Publishing, London, UK (2004).